Harlan Krumholz/LinkedIn
Dec 11, 2025, 12:50
Harlan Krumholz on Half-Life of Evidence and The Need for Real-Time Trials
Harlan Krumholz, Harold H. Hines Jr. Professor at Yale University, shared on LinkedIn:
”Clinical trials rarely come with expiration dates.
Yet the patients we treat today are not the same as those studied 40 years ago.
New trials on beta blockers after myocardial infarction highlight how much cardiology has changed, and how slowly our evidence adapts.
This is not simply about one therapy.
It is about the half-life of evidence and the need for modern, pragmatic, real-time trials that keep pace with evolving practice.
I explored this in my latest piece.”
Read the full article here.
Stay updated with Hemostasis Today.
-
Aug 11, 2026, 11:38Maria Hadjidemetriou: The Patient Perspective in Thalassemia Care
-
Aug 11, 2026, 11:04Wolfgang Miesbach: The Critical Need for Tailored Dosing in VWD
-
Aug 11, 2026, 08:20Hasan Abbas Zaheer: Strengthening Universal Access to Safe Blood in Pakistan
-
Aug 11, 2026, 08:07Nicola Pozzi: Advancing Hemostasis Through Scientific Collaboration at Hemostasis GRC
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:41Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care